vs
Apellis Pharmaceuticals, Inc.（APLS）与INTERPARFUMS INC（IPAR）财务数据对比。点击上方公司名可切换其他公司
INTERPARFUMS INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.9倍（$386.2M vs $199.9M），INTERPARFUMS INC净利率更高（7.3% vs -29.5%，领先36.8%），INTERPARFUMS INC同比增速更快（6.8% vs -5.9%），INTERPARFUMS INC自由现金流更多（$145.0M vs $-14.3M），过去两年INTERPARFUMS INC的营收复合增速更高（9.2% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Inter Parfums Inc是全球知名的高端香水企业，开发、生产并销售多款授权香水、身体护理及相关美妆产品，与多家顶级奢侈时尚生活方式品牌合作推出联名香氛系列，产品覆盖全球主要市场，通过百货、美妆专营店及官方电商渠道触达消费者。
APLS vs IPAR — 直观对比
营收规模更大
IPAR
是对方的1.9倍
$199.9M
营收增速更快
IPAR
高出12.8%
-5.9%
净利率更高
IPAR
高出36.8%
-29.5%
自由现金流更多
IPAR
多$159.3M
$-14.3M
两年增速更快
IPAR
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $386.2M |
| 净利润 | $-59.0M | $28.1M |
| 毛利率 | — | 61.5% |
| 营业利润率 | -25.6% | 7.1% |
| 净利率 | -29.5% | 7.3% |
| 营收同比 | -5.9% | 6.8% |
| 净利润同比 | -62.2% | 16.0% |
| 每股收益（稀释后） | $-0.40 | $0.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSIPAR
| Q4 25 | $199.9M | $386.2M | ||
| Q3 25 | $458.6M | $429.6M | ||
| Q2 25 | $178.5M | $333.9M | ||
| Q1 25 | $166.8M | $338.8M | ||
| Q4 24 | $212.5M | $361.5M | ||
| Q3 24 | $196.8M | $424.6M | ||
| Q2 24 | $199.7M | $342.2M | ||
| Q1 24 | $172.3M | $324.0M |
净利润APLSIPAR
| Q4 25 | $-59.0M | $28.1M | ||
| Q3 25 | $215.7M | $65.8M | ||
| Q2 25 | $-42.2M | $32.0M | ||
| Q1 25 | $-92.2M | $42.5M | ||
| Q4 24 | $-36.4M | $24.2M | ||
| Q3 24 | $-57.4M | $62.3M | ||
| Q2 24 | $-37.7M | $36.8M | ||
| Q1 24 | $-66.4M | $41.0M |
毛利率APLSIPAR
| Q4 25 | — | 61.5% | ||
| Q3 25 | — | 63.5% | ||
| Q2 25 | — | 66.2% | ||
| Q1 25 | — | 63.7% | ||
| Q4 24 | — | 64.5% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 64.5% | ||
| Q1 24 | — | 62.5% |
营业利润率APLSIPAR
| Q4 25 | -25.6% | 7.1% | ||
| Q3 25 | 48.7% | 25.3% | ||
| Q2 25 | -18.6% | 17.7% | ||
| Q1 25 | -50.0% | 22.2% | ||
| Q4 24 | -12.3% | 10.0% | ||
| Q3 24 | -24.0% | 25.0% | ||
| Q2 24 | -14.7% | 18.9% | ||
| Q1 24 | -36.0% | 21.0% |
净利率APLSIPAR
| Q4 25 | -29.5% | 7.3% | ||
| Q3 25 | 47.0% | 15.3% | ||
| Q2 25 | -23.6% | 9.6% | ||
| Q1 25 | -55.3% | 12.5% | ||
| Q4 24 | -17.1% | 6.7% | ||
| Q3 24 | -29.2% | 14.7% | ||
| Q2 24 | -18.9% | 10.8% | ||
| Q1 24 | -38.5% | 12.7% |
每股收益（稀释后）APLSIPAR
| Q4 25 | $-0.40 | $0.88 | ||
| Q3 25 | $1.67 | $2.05 | ||
| Q2 25 | $-0.33 | $0.99 | ||
| Q1 25 | $-0.74 | $1.32 | ||
| Q4 24 | $-0.30 | $0.78 | ||
| Q3 24 | $-0.46 | $1.93 | ||
| Q2 24 | $-0.30 | $1.14 | ||
| Q1 24 | $-0.54 | $1.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $137.1M |
| 总债务越低越好 | — | $176.0M |
| 股东权益账面价值 | $370.1M | $880.7M |
| 总资产 | $1.1B | $1.6B |
| 负债/权益比越低杠杆越低 | — | 0.20× |
8季度趋势，按日历期对齐
现金及短期投资APLSIPAR
| Q4 25 | $466.2M | $137.1M | ||
| Q3 25 | $479.2M | $77.5M | ||
| Q2 25 | $370.0M | $53.9M | ||
| Q1 25 | $358.4M | $75.3M | ||
| Q4 24 | $411.3M | $109.3M | ||
| Q3 24 | $396.9M | $78.8M | ||
| Q2 24 | $360.1M | $37.7M | ||
| Q1 24 | $325.9M | $76.1M |
总债务APLSIPAR
| Q4 25 | — | $176.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $157.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSIPAR
| Q4 25 | $370.1M | $880.7M | ||
| Q3 25 | $401.2M | $870.9M | ||
| Q2 25 | $156.3M | $839.4M | ||
| Q1 25 | $164.2M | $788.6M | ||
| Q4 24 | $228.5M | $744.9M | ||
| Q3 24 | $237.1M | $778.5M | ||
| Q2 24 | $264.3M | $717.1M | ||
| Q1 24 | $266.7M | $708.1M |
总资产APLSIPAR
| Q4 25 | $1.1B | $1.6B | ||
| Q3 25 | $1.1B | $1.6B | ||
| Q2 25 | $821.4M | $1.6B | ||
| Q1 25 | $807.3M | $1.4B | ||
| Q4 24 | $885.1M | $1.4B | ||
| Q3 24 | $901.9M | $1.5B | ||
| Q2 24 | $904.5M | $1.4B | ||
| Q1 24 | $831.9M | $1.3B |
负债/权益比APLSIPAR
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $146.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $145.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 37.5% |
| 资本支出强度资本支出/营收 | 0.1% | 0.4% |
| 现金转化率经营现金流/净利润 | — | 5.21× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $190.5M |
8季度趋势，按日历期对齐
经营现金流APLSIPAR
| Q4 25 | $-14.2M | $146.5M | ||
| Q3 25 | $108.5M | $63.9M | ||
| Q2 25 | $4.4M | $11.9M | ||
| Q1 25 | $-53.4M | $-7.4M | ||
| Q4 24 | $19.4M | $138.0M | ||
| Q3 24 | $34.1M | $76.1M | ||
| Q2 24 | $-8.3M | $25.5M | ||
| Q1 24 | $-133.0M | $-52.0M |
自由现金流APLSIPAR
| Q4 25 | $-14.3M | $145.0M | ||
| Q3 25 | $108.3M | $57.6M | ||
| Q2 25 | $4.4M | $-3.3M | ||
| Q1 25 | $-53.4M | $-8.8M | ||
| Q4 24 | $19.3M | $136.1M | ||
| Q3 24 | — | $75.4M | ||
| Q2 24 | $-8.4M | $24.4M | ||
| Q1 24 | $-133.3M | $-53.0M |
自由现金流率APLSIPAR
| Q4 25 | -7.1% | 37.5% | ||
| Q3 25 | 23.6% | 13.4% | ||
| Q2 25 | 2.5% | -1.0% | ||
| Q1 25 | -32.0% | -2.6% | ||
| Q4 24 | 9.1% | 37.7% | ||
| Q3 24 | — | 17.8% | ||
| Q2 24 | -4.2% | 7.1% | ||
| Q1 24 | -77.3% | -16.4% |
资本支出强度APLSIPAR
| Q4 25 | 0.1% | 0.4% | ||
| Q3 25 | 0.0% | 1.5% | ||
| Q2 25 | 0.0% | 4.5% | ||
| Q1 25 | 0.0% | 0.4% | ||
| Q4 24 | 0.0% | 0.5% | ||
| Q3 24 | 0.0% | 0.2% | ||
| Q2 24 | 0.0% | 0.3% | ||
| Q1 24 | 0.2% | 0.3% |
现金转化率APLSIPAR
| Q4 25 | — | 5.21× | ||
| Q3 25 | 0.50× | 0.97× | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | — | -0.17× | ||
| Q4 24 | — | 5.69× | ||
| Q3 24 | — | 1.22× | ||
| Q2 24 | — | 0.69× | ||
| Q1 24 | — | -1.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
IPAR
| European Based Operations | $232.7M | 60% |
| United States Based Operations | $155.2M | 40% |
